
810-4 Pexelizumab, a C5 complement inhibitor, reduces 30-day mortality in patients undergoing coronary artery bypass surgery or receiving reperfusion therapy for acute myocardial infarction
Frans J Van de Werf, Paul W Armstrong, Jerrold Levy, Christopher B Granger, Robert M Califf, Peter X Adams, Michael VanderLaan, Christopher Mojcik, Thomas G Todaro, Edward D VernierVolume:
43
Année:
2004
Langue:
english
DOI:
10.1016/s0735-1097(04)92006-2
Fichier:
PDF, 48 KB
english, 2004